MARKET

EVFM

EVFM

Evofem
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.280
-0.990
-30.28%
After Hours: 2.320 +0.04 +1.75% 19:58 03/05 EST
OPEN
2.414
PREV CLOSE
3.270
HIGH
2.470
LOW
2.010
VOLUME
15.72M
TURNOVER
--
52 WEEK HIGH
6.87
52 WEEK LOW
1.910
MARKET CAP
185.32M
P/E (TTM)
-1.1817
1D
5D
1M
3M
1Y
5Y
What Type Of Shareholders Make Up Evofem Biosciences, Inc.'s (NASDAQ:EVFM) Share Registry?
A look at the shareholders of Evofem Biosciences, Inc. ( NASDAQ:EVFM ) can tell us which group is most powerful...
Simply Wall St. · 1d ago
Mid-Afternoon Market Update: Nasdaq Surges 150 Points; Calyxt Shares Slide
Toward the end of trading Friday, the Dow traded up 1.5% to 31,388.89 while the NASDAQ rose 1.18% to 12,874.20. The S&P also rose, gaining 1.62% to 3,829.59.
Benzinga · 1d ago
SIFY, WTI, OPEN and EVFM among notable midday movers
Gainers: Second Sight Medical Products (EYES) +337%.AMTD International (HKIB) +27%.Sify Technologies Limited (SIFY) +26%.Boqii Holding Limited (BQ) +25%.ChromaDex Corporation (CDXC) +22%.W&T Offshore (WTI) +21%.Anchiano Therapeutics (ANCN) +18%.Purple Inno...
Seekingalpha · 1d ago
Mid-Day Market Update: Dow Tumbles Over 100 Points; Sify Technologies Shares Spike Higher
Midway through trading Friday, the Dow traded down 0.37% to 30,808.38 while the NASDAQ fell 1.75% to 12,500.69. The S&P also fell, dropping 0.71% to 3,741.87.
Benzinga · 1d ago
Second Sight Medical Products, XTL Biopharmaceuticals leads healthcare gainers; Evofem Biosciences, T2 Biosystems among major losers
Gainers: Second Sight Medical Products (EYES) +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences (EVFM) -34%, T2 Biosystems (TTOO) -25%, IM...
Seekingalpha · 2d ago
ROCE Insights For Evofem Biosciences
In Q4, Evofem Biosciences (NASDAQ:EVFM) posted sales of $168.00 thousand. Earnings were up 37.07%, but Evofem Biosciences still reported an overall loss of $35.85 million. In Q3, Evofem Biosciences brought in $278.00 thousand in sales but lost $26.16 milli...
Benzinga · 2d ago
Mid-Morning Market Update: Markets Mixed; Big Lots Earnings Top Views
Following the market opening Friday, the Dow traded up 0.32% to 31,024.11 while the NASDAQ fell 0.5% to 12,659.24. The S&P also rose, gaining 0.09% to 3,771.85.
Benzinga · 2d ago
Evofem shares down on Q4 miss, mixed-shelf offering
Evofem Biosciences (EVFM) posted Q4 earnings that missed estimates and has filed for a mixed-shelf securities offering of $150M, sending the company's shares down 25% premarket.Q4 net product sales were about $170K, missing
Seekingalpha · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of EVFM. Analyze the recent business situations of Evofem through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average EVFM stock price target is 7.60 with a high estimate of 15.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 208
Institutional Holdings: 55.05M
% Owned: 67.73%
Shares Outstanding: 81.28M
TypeInstitutionsShares
Increased
30
2.35M
New
45
-3.99M
Decreased
20
1.49M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Director
Thomas Lynch
President/Chief Executive Officer/Director
Saundra Pelletier
Chief Financial Officer
Justin File
Executive Vice President/General Counsel/Secretary
Alexander Fitzpatrick
Other
Russell Barrans
Other
Russ Barrans
Other
Kelly Culwell
Independent Director
Gillian Greer
Independent Director
William Hall
Independent Director
Kim Kamdar
Independent Director
Tony O'Brien
Independent Director
Lisa Rarick
Independent Director
Colin Rutherford
No Data
  • All
  • Financials
  • Insiders
More
About EVFM
Evofem Biosciences Inc, formerly Neothetics, Inc., is a clinical-stage specialty biopharmaceutical company. The Company develops products to address unmet needs in women's sexual and reproductive health. The Company’s product Amphora, is a Multipurpose Vaginal pH Regulator (MVP-R) designed to regulate vaginal pH to within the normal range of 3.5 to 4.5 even in the presence of semen. This maintains an acidic environment which is inhospitable to sperm as well as certain viral and bacterial pathogens associated with sexually transmitted infections. Amphora is used to prevent urogenital chlamydia and gonorrhea in women. The Company is in the second Phase III clinical trial of Amphora for prevention of pregnancy (AMP002). The Company is currently designing a Phase IIb trial for its second product candidate, a MVP-R to reduce the recurrence of bacterial vaginosis.

Webull offers kinds of Evofem Biosciences Inc stock information, including NASDAQ:EVFM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVFM stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading EVFM stock methods without spending real money on the virtual paper trading platform.